Abstract
Parkinson’s disease (PD) is a degenerative neurological syndrome, which is characterized by the preferential death of dopaminergic (DAergic) neurons in the Substantia Nigra. The pathogenesis of this disorder remains poorly understood and PD is still incurable. Current drug treatments are aimed primarily for the treatment of symptoms to improve the quality of life. Therefore, there is a need to find out new therapeutic strategies that not only provide symptomatic relief but also halt or reverse the neuronal damage hampering PD progression. Oxidative stress has been identified as one of the major contributors for the nigral loss in both sporadic and genetic forms of PD. In this review we first evaluate the current literature that links oxidative stress and mitochondrial dysfunction to PD. We then consider the results obtained through the treatment of animal models or PD patients with molecules that prevent oxidative stress or reduce mitochondrial dysfunction.
Keywords: Antioxidants, iron chelators, mitochondria, oxidative stress, radical scavengers, reactive oxygen species.
Graphical Abstract
Current Neuropharmacology
Title:Anti-Oxidants in Parkinson’s Disease Therapy: A Critical Point of View
Volume: 14 Issue: 3
Author(s): Roberta Filograna, Mariano Beltramini, Luigi Bubacco and Marco Bisaglia
Affiliation:
Keywords: Antioxidants, iron chelators, mitochondria, oxidative stress, radical scavengers, reactive oxygen species.
Abstract: Parkinson’s disease (PD) is a degenerative neurological syndrome, which is characterized by the preferential death of dopaminergic (DAergic) neurons in the Substantia Nigra. The pathogenesis of this disorder remains poorly understood and PD is still incurable. Current drug treatments are aimed primarily for the treatment of symptoms to improve the quality of life. Therefore, there is a need to find out new therapeutic strategies that not only provide symptomatic relief but also halt or reverse the neuronal damage hampering PD progression. Oxidative stress has been identified as one of the major contributors for the nigral loss in both sporadic and genetic forms of PD. In this review we first evaluate the current literature that links oxidative stress and mitochondrial dysfunction to PD. We then consider the results obtained through the treatment of animal models or PD patients with molecules that prevent oxidative stress or reduce mitochondrial dysfunction.
Export Options
About this article
Cite this article as:
Filograna Roberta, Beltramini Mariano, Bubacco Luigi and Bisaglia Marco, Anti-Oxidants in Parkinson’s Disease Therapy: A Critical Point of View, Current Neuropharmacology 2016; 14 (3) . https://dx.doi.org/10.2174/1570159X13666151030102718
DOI https://dx.doi.org/10.2174/1570159X13666151030102718 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Cell-Permeable Peptide Inhibitor of c-Jun NH2-Terminal Kinase for the Treatment of Diabetes
Current Bioactive Compounds Ghrelin and Motilin in the Gastrointestinal System
Current Pharmaceutical Design Neurocognitive Monitoring and Care During Pediatric Cardiopulmonary Bypass — Current and Future Directions
Current Cardiology Reviews ATP-Sensitive K+ Channel Openers: Old Drugs with New Clinical Benefits for the Heart
Current Vascular Pharmacology Oral Antiplatelet Therapy for Acute Coronary Syndromes: Aspirin, P2Y12 Inhibition and Thrombin Receptor Antagonists
Current Drug Targets Cardiac Surgery and Inflammation: The Inflammatory Response and Strategies to Reduce the Systemic Inflammatory Response Syndrome
Current Cardiology Reviews Oxidative Stress and Altered Mitochondrial Function in Neurodegenerative Diseases: Lessons From Mouse Models
CNS & Neurological Disorders - Drug Targets Recent Advances in Adenovirus-mediated Gene Therapy for Cerebral Ischemia
Current Gene Therapy Exploiting the Diversity of the Heat-Shock Protein Family for Primary and Secondary Tauopathy Therapeutics
Current Neuropharmacology Human Mesenchymal Stem Cell-derived Exosomes Reduce Ischemia/Reperfusion Injury by the Inhibitions of Apoptosis and Autophagy
Current Pharmaceutical Design New Frontiers in the Management of Acute Coronary Syndromes: Cangrelor and Elinogrel
Recent Patents on Cardiovascular Drug Discovery Oxidative Brain Damage by Peroxynitrite in Bacterial Meningitis: A Target for Adjunctive Therapy?
Current Medicinal Chemistry - Central Nervous System Agents Meet Our Editorial Board Member
Current Pharmaceutical Biotechnology Editorial (Thematic Issue: Modifying Cardiovascular Risk Factors: Current Opinion and Future Trends)
Current Pharmaceutical Design Cannabinoid CB2 Receptors in Health and Disease
Current Medicinal Chemistry Chemistry and Pharmacology of Bioactive Molecule -Coenzyme Q10: A Brief Note
Current Bioactive Compounds Effects of Static Magnetic Fields on Blood Pressure in Animals and Humans
Current Hypertension Reviews Endothelin and the Ischaemic Heart
Current Vascular Pharmacology Current Pharmacological Treatment of Nonalcoholic Fatty Liver
Current Medicinal Chemistry Coated with Nanomaterials Intraocular Lenses, Ophthalmic and Human Body Implantable Devices with High Catalytic Antioxidant Activities: A New Nanotechnology Strategy of Peroxidase Cellular Enzyme Mimics Increasing the Biocompatibility and Therapeutic Deployment of the Medical Prosthetic Device
Recent Patents on Drug Delivery & Formulation